A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours.
Phase of Trial: Phase I/II
Latest Information Update: 23 Apr 2014
At a glance
- Drugs L19-IL2 fusion protein (Primary)
- Indications Renal cell carcinoma; Solid tumours
- Focus Adverse reactions
- Sponsors Philogen
- 03 Jul 2013 New source identified and integrated (German Clinical Trials Register; DRKS00004061).
- 06 Feb 2010 New trial record